Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies Therapy
Data on allergies therapy described by researchers at Cukurova University, Department of Oncology
April 10th, 2007
Researchers detail in "Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication," new data in allergies. "In spite of the development of new antifungal drugs, amphotericin B deoxycholate (d-AMB) remains the gold standard in the treatment of severe fungal infections in immunosuppressed hosts. However, d-AMB is a toxic drug, the most important dose-limiting toxicities being nephrotoxicity and infusion-related allergic reactions," investigators in Adana, Turkey report. "Lipid and liposomal formulations of d-AMB have relatively lower toxicity and are considered alternative choices. However,...
Source: Drug Law Weekly (2007-04-10)
|
